On Monday, the European Commission approved GSK plc’s (NYSE:GSK) Jemperli (dostarlimab) in combination with chemotherapy (carboplatin and paclitaxel) for first-line treatment of adult patients ...

GSK plc GSK announced that the European Commission has granted approval for the expanded use of Jemperli (dostarlimab) plus chemotherapy to include all adult patients with primary, advanced or ...

European Commission approved GSK's Jemperli with chemotherapy for advanced or recurrent endometrial cancer, covering 75% of cases. RUBY trial showed Jemperli combo reduced death risk by 31% and ...

On Monday, the European Commission approved GSK plc’s (NYSE:GSK) Jemperli (dostarlimab) in combination with chemotherapy (carboplatin and paclitaxel) for first-line treatment of adult patients with ...

GSK's latecomer to the PD-1/PD-L1 inhibitor ... and has just reported results of a trial comparing Jemperli (dostarlimab) to Merck & Co's market-leading Keytruda (pembrolizumab), showing it ...

Jemperli a Key Oncology Drug for GSK In the first nine months of 2024, Jemperli recorded sales worth £318 million. Sales of the drug are being driven by new patient starts in the United States.

The FDA has cleared GSK's PD-1 inhibitor Jemperli as a treatment ... The approval is based on the RUBY trial, which showed that Jemperli (dostarlimab) given with carboplatin and paclitaxel ...

GSK's oncology sales increased 98% in 2024, and reflects strong demand and potentially new launches or indications for cancer therapies.

GSK, Gilead Sciences, BieGene, and Nuvalent among others. . Key Non-Small Cell Lung Cancer Therapies: Firmonertinib, Belrestotug (Eos-448) + Jemperli (Dostarlimab), Sacituzumab Tirumotecan (Mk ...

Anaptys has also discovered multiple therapeutic antibodies licensed to GSK in a financial collaboration for immuno-oncology, including an anti-PD-1 antagonist (Jemperli (dostarlimab-gxly)) and an ...

Anaptys has also discovered multiple therapeutic antibodies licensed to GSK in a financial collaboration for immuno-oncology, including an anti-PD-1 antagonist (Jemperli (dostarlimab-gxly)) and an ...